Warrants - Additional Information (Details)			1 Months Ended	12 Months Ended
	Nov. 02, 2023 USD ($) $ / shares shares	Oct. 03, 2023 USD ($) PValue TradingDay $ / shares shares	Nov. 30, 2023 $ / shares shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Class of Warrant or Right [Line Items]
Proceeds | $				$ 1,278,000	$ 3,560,000
Description of public warrants right to call				The Company has the right to “call” any portion of a holder’s public warrants by delivering a call notice to the holder within 30 days after Company publicly announces an increase in pepinemab-treated patients relative to placebo-treated patients, with statistical significance having a p-value of less than or equal to 0.05, in the change of the FDG-PET standard uptake value ratio for brain metabolism between baseline and month 12 as assessed by [18F]fluorodeoxyglucose (FDG)-PET in the resting state following administration of 40 mg/kg pepinemab or placebo, as applicable, as described in the protocol for the Company’s SIGNAL-AD Alzheimer’s disease study and the associated Statistical Analysis Plan. After delivery of a call notice, the public warrants will continue to be exercisable. Each public warrant will be canceled and no longer exercisable to the extent the holder fails to timely exercise the public warrant for the called portion thereof within 20 trading days following the Company’s issuance of a call notice.
November Warrant Offering
Class of Warrant or Right [Line Items]
Sale of stock, transaction date	Nov. 02, 2023
Proceeds | $	$ 17,000
Public Warrants
Class of Warrant or Right [Line Items]
Sale of stock, transaction date		Oct. 03, 2023
Warrants expiration period		5 years
Call notice period		30 days
Number of trading days | TradingDay		20
Issuance date fair value | $		$ 3,500,000
Public Warrants | Maximum
Class of Warrant or Right [Line Items]
Statistical significance of p-value | PValue		0.05
Pre-funded Warrants
Class of Warrant or Right [Line Items]
Proceeds | $		$ 1,900,000
Pre-funded Warrants and Public Warrants
Class of Warrant or Right [Line Items]
Shares issued, price per share | $ / shares		$ 13.99
Proceeds | $		$ 9,600,000
Private Placement Warrants
Class of Warrant or Right [Line Items]
Warrants expiration period			5 years
Common Stock | November Warrant Offering
Class of Warrant or Right [Line Items]
Number of shares sold	37,694
Shares issued, price per share | $ / shares	$ 1.75
Common Stock | Public Warrants
Class of Warrant or Right [Line Items]
Number of shares sold		542,857
Warrants issued		542,857
Shares issued, price per share | $ / shares		$ 14
Notice period to change beneficial ownership limitation		61 days
Maximum beneficial ownership limitation		9.99%
Common Stock | Common Warrants | November Warrant Offering
Class of Warrant or Right [Line Items]
Warrants issued	37,694
Common Stock | Pre-funded Warrants
Class of Warrant or Right [Line Items]
Number of shares sold		142,857
Warrants issued		142,857
Shares issued, price per share | $ / shares		$ 0.0001
Common Stock | Pre-funded Warrants and Public Warrants
Class of Warrant or Right [Line Items]
Warrants issued		142,857
Common Stock | Private Placement Warrants | November Warrant Offering
Class of Warrant or Right [Line Items]
Number of shares sold			37,694
Warrants issued			37,694
Shares issued, price per share | $ / shares			$ 1.75